UCLA Develops New Alzheimer's Disease Therapeutic
A new development that targets GABA-A receptors in parvalbumin interneurons.
Dr. Varghese John, Dr. Istvan Mody, and colleagues were highlighted in a UCLA article about their recent therapeutic development, targeting parvalbumin interneurons to revitalize cognitive deficits in an amyloid-based mouse model of Alzheimer's disease.
Related Articles
Healthy Body. Healthy Mind.
In the Summer Edition of Keiro Connect, Dr. Kevin Bickart discussed physical activity, including dancing, to improve brain health and prevent dementia ...
A More Inclusive Framework for Alzheimer’s Disease
The Easton Center, ELHA Lab, UCLA Neurology, Alzheimer's Los Angeles, and community leaders are working together bridging the gap between health disparities ...
An In-Depth Interview on Various Neurodegenerative Diseases
Dr. Keith Vossel was interviewed by Dr. Marc Siegel from Doctor Radio/Sirius XM about a wide spectrum of neurodegenerative diseases, including ...
Sundowning Occurs in Patients with Alzheimer’s and Dementia
Dr. Keith Vossel was interviewed in a Forbes Health article about sundowning and the symptoms that patients with Alzheimer’s and dementia may experience ...